This week, Dean Omar, the plaintiffs’ firm based in Dallas, has secured a $260 million jury award in a talc-related case. This outcome follows closely on the heels of a $45 million mesothelioma talc verdict from less than two months ago. The continuing legal challenges for Johnson & Johnson are expanding, as this latest decision adds to the company’s existing litigation woes.
In a separate development, the Ozempic multidistrict litigation (MDL) shows no signs of slowing down despite the recent death of the presiding judge. The case, which involves claims related to the diabetes medication, is progressing under new judicial oversight.
For more detailed coverage on these trials and their implications, you can access the full article on Law.com.